BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 9
• 10
• 11
• 12
• 13
• 15
• 16
• 17
• 18
• 19
• 20
• 22
• 23
• 24
• 25
• 26
• 27
• 30
• 31

• Press Releases

  Kedrion Activates Nationwide Distribution Network for QIVIGY® in the U.S.

  March 6, 2026

   · 

  6 min read
• Press Releases

  CARsgen Therapeutics Announces 2025 Annual Results

  March 6, 2026

   · 

  12 min read
• 

  Huntington’s disease

  FDA Official Fires Back at UniQure, Doubles Down on Sham-Controlled Trial

  UniQure does not have to drill placebo burr holes in the skulls of patients with Huntington’s disease, an unnamed FDA senior official said on Thursday. Instead, the company would anesthetize them and put “one to three nicks” in their scalp.

  March 6, 2026

   · 

  2 min read

   · 

  Tristan Manalac
• Press Releases

  Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - March 6, 2026

  March 6, 2026

   · 

  1 min read
• Press Releases

  Immuneering Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

  March 6, 2026

   · 

  13 min read
• Press Releases

  TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2026 Annual Meeting

  March 6, 2026

   · 

  13 min read
• Press Releases

  ClearPoint Neuro to Announce Fourth Quarter and Full Year 2025 Results March 17, 2026

  March 6, 2026

   · 

  4 min read
• 

  Immuno-oncology

  J&J Wins Third National Priority Approval for Multiple Myeloma Combo

  The FDA granted Johnson & Johnson a Commissioner’s National Priority Voucher in December 2025 after the combination of Darzalex and Tecvayli improved progression-free survival by 83%. The new approval is for second-line treatment of the blood cancer.

  March 6, 2026

   · 

  2 min read

   · 

  Tristan Manalac
• Press Releases

  Catalyst Pharmaceuticals to Showcase Real‑World Findings in Duchenne Muscular Dystrophy and Host Vamorolone-Focused Symposium at the 2026 MDA Clinical & Scientific Conference

  March 6, 2026

   · 

  4 min read
• Press Releases

  Novartis shareholders approve all resolutions proposed by the Board of Directors at the 2026 Annual General Meeting

  March 6, 2026

   · 

  4 min read